In a groundbreaking initiative to treat severe mental health conditions, a new research group in Cambridgeshire is conducting clinical trials to investigate the potential benefits of empathogens and psychedelics for PTSD treatment
Approximately 30% of individuals with severe mental illnesses find that conventional treatments are not effective enough. The trials aim to help people who have not responded to traditional treatments, such as talking therapies and antidepressants.
30% of individuals with severe mental illnesses find that conventional treatments are not effective enough
Cambridge Psychedelic Research Group
The research group, a collaboration between CPFT, Cambridge University Hospitals NHS Foundation Trust, and the University of Cambridge, has secured a Home Office license to conduct the trials.
What are psychedelics?
Psychedelics are a type of drug that changes a person’s perception of reality. Also known as ‘hallucinogens’, they make a person see, feel and hear things that aren’t real or distort their interpretation of what’s going on around them.
Psychedelics target specific centres of the brain to alter its understanding of sensory input.
First Trial of TSND-20: Psychedelics for PTSD
The group’s initial study is evaluating the effects of TSND-201, a rapid-acting neuroplastogen, on individuals with post-traumatic stress disorder (PTSD).
An estimated one in ten people in the UK will experience PTSD in their lifetime, and current treatments, such as talking therapies and antidepressant medications, do not work for everyone.
Dr. Liliana Galindo, a consultant psychiatrist and affiliated assistant professor at the University of Cambridge, expressed optimism about the potential of this research to address persistent mental health conditions. Galindo stated: “We are excited to join the growing psychedelic research field with this new local partnership and help to develop the next wave of neuropsychiatric treatments.”
Hope for Individuals with PTSD
PTSD affects a significant number of people in the UK, and current treatments often fall short. TSND-201 could offer a new avenue of hope for those who have not benefited from conventional approaches.
